Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Expert Rev Clin Immunol. 2021 Jun 8;17(7):727–736. doi: 10.1080/1744666X.2021.1935877

Figure 2. Targeting oral dysbiosis to diagnose and treat gut and liver diseases.

Figure 2.

Monitoring of oral health and the oral dysbiosis (e.g., the abundance of oral pathobionts) could be used as a biomarker for inflammatory bowel disease (IBD), colorectal cancer (CRC), metabolic fatty liver disease (MAFLD), and nonalcoholic steatohepatitis (NASH). Also, optimal oral care has the potential to reduce the risk for these diseases.